Patents by Inventor Volker Germaschewski

Volker Germaschewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-PD-L1 antibodies
    Patent number: 12209128
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: January 28, 2025
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen Douglas Gillies
  • ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF
    Publication number: 20250026813
    Abstract: The present invention relates to antibodies that are specific for SARS-CoV-2. The present invention also provides methods of treatment, uses, pharmaceutical compositions and kits comprising the antibodies.
    Type: Application
    Filed: October 27, 2021
    Publication date: January 23, 2025
    Inventors: Paul Kellam, Anne Palser, Volker Germaschewski, Simon James Watson, Benjamin David Grimshaw, Spela Binter, Jaroslaw Michal Szary, Margot Billaud, Robert Rowlands, Aishwarya Krishna, Huan-Chun Lin, Cheng-Yuan Yang, Li-Ying Liou
  • ANTI-PD-L1 AND IL-2 CYTOKINES
    Publication number: 20240360218
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: February 29, 2024
    Publication date: October 31, 2024
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
    Publication number: 20240343810
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: March 26, 2024
    Publication date: October 17, 2024
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • ANTAGONISTS AND AGONISTS OF THE TRANSFERRIN RECEPTOR-2 FOR USE IN THE TREATMENT OF DISEASES OF THE BONE
    Publication number: 20240199755
    Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases. The invention also relates to a transferrin receptor 2 inhibitor for use in the treatment of bone diseases, iron metabolism disorders or hematopoietic disorders.
    Type: Application
    Filed: December 8, 2023
    Publication date: June 20, 2024
    Inventors: Martina RAUNER, Lorenz HOFBAUER, Uwe PLATZBECKER, Ulrike BASCHANT, Igor THEURL, Volker GERMASCHEWSKI
  • ANTI-ICOS ANTIBODIES
    Publication number: 20240158502
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: November 1, 2023
    Publication date: May 16, 2024
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Nahida PARVEEN, Robert ROWLANDS, Gwenoline BORHIS
  • Anti-PD-L1 and IL-2 cytokines
    Patent number: 11965026
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: April 23, 2024
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen Douglas Gillies
  • Anti-ICOS antibodies
    Patent number: 11858996
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 2, 2024
    Assignee: KYMAB LIMITED
    Inventors: Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Volker Germaschewski, Ian Kirby, Miha Kosmac, Nahida Parveen, Robert Rowlands, Gwenoline Borhis
  • MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
    Publication number: 20230312720
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: September 1, 2022
    Publication date: October 5, 2023
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Ian KIRBY, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • METHODS, REGIMENS, COMBINATIONS & ANTAGONISTS
    Publication number: 20230233675
    Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
    Type: Application
    Filed: August 11, 2022
    Publication date: July 27, 2023
    Applicant: Kymab Limited
    Inventors: Volker GERMASCHEWSKI, Igor THEURL, Martin YATEMAN, Jasper CLUBE, Steve ARKINSTALL
  • TIGIT ANTIBODIES, ENCODING NUCLEIC ACIDS AND METHODS OF USING SAID ANTIBODIES IN VIVO
    Publication number: 20230192847
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: July 15, 2022
    Publication date: June 22, 2023
    Inventors: Joana de Abreu CARVALHO, Rachael Jane KIMBER, Jamie Ian CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE, Stephen Douglas GILLIES
  • MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
    Publication number: 20230192859
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: June 20, 2017
    Publication date: June 22, 2023
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • Methods, regimens, combinations and antagonists
    Patent number: 11648308
    Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 16, 2023
    Assignee: Kymab Limited
    Inventors: Volker Germaschewski, Igor Theurl, Martin Yateman, Jasper Clube, Steve Arkinstall
  • TREATMENT FOR PHYSIOLOGICAL IRON OVERLOAD
    Publication number: 20230025129
    Abstract: Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.
    Type: Application
    Filed: November 27, 2020
    Publication date: January 26, 2023
    Inventors: Matthew WAKE, Volker GERMASCHEWSKI, Igor THEURL, Jonathan Leslie PAPWORTH, Delphine MEYNARD
  • ANTI-ICOS ANTIBODIES
    Publication number: 20220403029
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: April 22, 2022
    Publication date: December 22, 2022
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • ANTI-ICOS ANTIBODIES
    Publication number: 20220380467
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: April 22, 2022
    Publication date: December 1, 2022
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo
    Patent number: 11440960
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 13, 2022
    Assignee: KYMAB LIMITED
    Inventors: Joana de Abreu Carvalho, Rachael Jane Kimber, Jamie Ian Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Matthew John McCourt, Richard Charles Alfred Sainson, Mohammed Hanif Ali, E-Chiang Lee, Stephen Douglas Gillies
  • ANTAGONISTS
    Publication number: 20220073598
    Abstract: The invention relates to Bone Morphogenetic Protein 6 (BMP6) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.
    Type: Application
    Filed: August 15, 2019
    Publication date: March 10, 2022
    Inventors: Volker GERMASCHEWSKI, Igor THEURL, Joana de Abreu CARVALHO, Morgane Marie LECOINTRE, Jonathan Leslie PAPWORTH, Luke Thomas BAYLISS, Verena PETZER
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20210380699
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: April 28, 2021
    Publication date: December 9, 2021
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • ANTAGONISTS AND AGONISTS OF THE TRANSFERRIN RECEPTOR-2 FOR USE IN THE TREATMENT OF DISEASES OF THE BONE
    Publication number: 20210214456
    Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases. The invention also relates to a transferrin receptor 2 inhibitor for use in the treatment of bone diseases, iron metabolism disorders or hematopoietic disorders.
    Type: Application
    Filed: June 11, 2019
    Publication date: July 15, 2021
    Inventors: Martina RAUNER, Lorenz HOFBAUER, Uwe PLATZBECKER, Ulrike BASCHANT, Igor THEURL, Volker GERMASCHEWSKI